SGS has entered into collaboration with Bavarian Nordic A/S, an international biotechnology company specializing in vaccines, to develop a new respiratory syncytial virus (RSV) challenge strain. This will assist with the advancement of a universal vaccine candidate designed to induce protective immune responses against both subtypes (A & B) of RSV. The project will build upon the results of phase II trials undertaken by Bavarian Nordic, and will include a human challenge study, which will...